Pediatric Neurology
Volume 30, Issue 1 , Pages 29-32 , January 2004

Physician preference for antiepileptic drug concentration testing

  • Robert J Baumann, MD

      Affiliations

    • Department of Neurology, College of Medicine, University of Kentucky, Lexington, Kentucky, USA
    • Department of Pediatrics, College of Medicine, University of Kentucky, Lexington, Kentucky, USA
    • Corresponding Author InformationCommunications should be addressed to:Dr. Baumann; Kentucky Clinic L445; University of Kentucky; Lexington, KY 40536-0284, USA.
    • ,
  • Melody Ryan, PharmD

      Affiliations

    • Department of Neurology, College of Medicine, University of Kentucky, Lexington, Kentucky, USA
    • Division of Pharmacy Practice and Science, College of Pharmacy, University of Kentucky, Lexington, Kentucky, USA
    • ,
  • Aaron Yelowitz, PhD

      Affiliations

    • Department of Economics, University of Kentucky, Lexington, Kentucky, USA

Received 10 April 2003 ,Accepted 5 June 2003.

References 

  1. Hauser WA, Hesdorffer DC. Remission, intractability, morality, and comorbidity of seizures. In:  Wyllie E editors. The treatment of epilepsy (Principles and practice). Philadelphia: Lippincott Williams & Wilkins; 2001;p. 139–145
  2. Leppik IE. Laboratory tests. In:  Engel J,  Pedley TA editor. Epilepsy (A comprehensive textbook). Philadelphia, New York: Lippincott-Raven; 1998;p. 811–817
  3. Birnbaum AK, Kriel RL, Cloyd JC. Pharmacokinetics in infancy, childhood, and adolescence. In:  Wyllie E editors. The treatment of epilepsy (Principles and practice). Philadelphia: Lippincott Williams & Wilkins; 2001;p. 741–757
  4. Kriel RL, Birnbaum AK, Cloyd JC. Antiepileptic drug therapy in children. In:  Swaiman KF,  Ashwal S editor. Pediatric neurology (Principles and practice). St. Louis: Mosby; 1999;p. 692–718
  5. Menkes JH, Sankar R. Paroxysmal disorders. In:  Menkes JH,  Sarnat HB editor. Child neurology. Philadelphia: Lippincott Williams & Wilkins; 2002;p. 919–1026
  6. Pichini S, Altieri I, Zuccaro P, Pacifici R. Drug monitoring in nonconventional biological fluids and matrices. Clin Pharmacokinet. 1996;30:211–228
  7. Rylance GW, Moreland TA. Saliva carbamazepine and phenytoin level monitoring. Arch Dis Child. 1981;56:637–640
  8. Bailey B, Klein J, Koren G. Noninvasive methods for drug measurement in pediatrics. Pediatr Clin North Am. 1997;44:15–26
  9. Child Neurology Society. Child Neurology Society Directory 2000. St. Paul, Minnesota: Child Neurology Society, 2000
  10. U. S. Census Bureau. Census regions and divisions of the United States. http://www.census.gov/geo/www/us_regdiv.pdf. 2002
  11. Tal A, Aviram M, Gorodischer R. Variations in theophylline concentrations detected by 24-hour saliva concentration profiles in ambulatory children with asthma. J Allergy Clin Immunol. 1990;86:238–243
  12. Rosenthal E, Hoffer E, Ben Aryeh H, Badarni S, Benderly A, Hemli Y. Use of saliva in home monitoring of carbamazepine levels. Epilepsia. 1995;36:72–74
  13. Stanaway L, Lambie DG, Johnson RH. Non-compliance with anticonvulsant therapy as a cause of seizures. N Z Med J. 1985;98:150–152
  14. Berndt ER. The U.S. pharmaceutical industry (Why major growth in times of cost containment?). Health Aff (Millwood). 2001;20:100–114
  15. Miles MV, Tennison MB, Greenwood RS, et al.  Evaluation of the Ames Seralyzer for the determination of carbamazepine, phenobarbital, and phenytoin concentrations in saliva. Ther Drug Monit. 1990;12:501–510
  16. Miles MV, Tennison MB, Greenwood RS. Intraindividual variability of carbamazepine, phenobarbital, and phenytoin concentrations in saliva. Ther Drug Monit. 1991;13:166–171
  17. Trnavska Z, Krejcova H, Tkaczykovam, Salcmanova Z, Elis J. Pharmacokinetics of lamotrigine (Lamictal) in plasma and saliva. Eur J Drug Metab Pharmacokinet 1991;3(Spec No 3):211-5
  18. Grim SA, Ryan M, Miles MV, et al.  Correlation of levetiracetam concentrations between serum and saliva. Ther Drug Monit. 2003;25:61–66
  19. Miles MV, Tang P, Glauser TA, et al. Topiramate concentrations in saliva: An alternative to serum monitoring. Pediatr Neurol 2003;29:143–7
  20. Leppik IE, Jacobs MP, Loewenson RB. Detection of adverse events by routine laboratory testing. [letter] Epilepsia. 1990;31:640
  21. Wyllie E, Wyllie R. Routine laboratory monitoring for serious adverse effects of antiepileptic medications (The controversy). Epilepsia. 1991;32(Suppl. 5):S74–S79
  22. Gorodischer R, Burtin P, Verjee Z, Hwang P, Koren G. Is saliva suitable for therapeutic monitoring of anticonvulsants in children (An evaluation in the routine clinical setting). Ther Drug Monit. 1997;19:637–642
  23. Dickinson RG, Hooper WD, King AR, Eadie MJ. Fallacious results from measuring salivary carbamazepine concentrations. Ther Drug Monit. 1985;7:41–45
  24. Baumann RJ, Wilson JF, Wiese HJ. Kentuckians' attitudes toward children with epilepsy. Epilepsia. 1995;36:1003–1008

PII: S0887-8994(03)00410-7

doi: 10.1016/S0887-8994(03)00410-7

Pediatric Neurology
Volume 30, Issue 1 , Pages 29-32 , January 2004

Article Tools